An ongoing shortage and increasing demand for a potential treatment for coronavirus could allow Bayer AG to obtain a rarely granted emergency use authorization from the US Food and Drug Administration.
Chloroquine phosphate and hydroxychloroquine, each old anti-malaria drugs, are being tested in the US and other countries as potential treatments for coronavirus after some reports suggest patients may improve